Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.30 | 03:09:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.30 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.5656 - 13.14 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 8.30 | USD |
Oncternal Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.57M | 2.96M | - | 785k | -39.48M | -13.34 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncternal Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.67 | 8.76 | 8.0295 | 8.27 | 5,773 | -0.37 | -4.27% |
| 1 Month | 8.78 | 9.88 | 8.0295 | 8.74 | 6,497 | -0.48 | -5.47% |
| 3 Months | 7.92 | 9.88 | 7.92 | 8.73 | 5,842 | 0.38 | 4.80% |
| 6 Months | 7.80 | 13.14 | 5.5656 | 9.65 | 68,909 | 0.50 | 6.41% |
| 1 Year | 6.70 | 13.14 | 5.5656 | 7.80 | 141,334 | 1.60 | 23.88% |
| 3 Years | 108.00 | 111.40 | 5.22 | 38.92 | 416,495 | -99.70 | -92.31% |
| 5 Years | 112.00 | 211.20 | 5.22 | 75.77 | 645,332 | -103.70 | -92.59% |
Oncternal Therapeutics Description
| Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |
